In recent years, CTLA-4 has been shown to play a crucial role in immune checkpoint-based therapeutics, especially in cancer treatment, by using monoclonal antibodies against the molecule (6). Moreover ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today highlights key scientific contributions in 2024-2025 that are shaping the future of cancer immunotherapy.

Studies performed during the past 2 years have provided a deeper understanding into the role of CTLA-4, which is expressed ... additional peripheral regulatory mechanisms ensure that the ...

Therefore, we summarized the potential mechanisms of PD-1/PD-L1 and CTLA-4 inhibitors in boosting the anti-tumor immunity and inducing transplant rejection. Figure 1 The balance between cancer ...

(1) Figure 2: Mechanism of action of immune checkpoint inhibitors” (adapted from Su 2024) (8) In vitro testing in activated T cells led to the discovery of LAG-3 as an inhibitory receptor, similar to ...

Checkpoint inhibitors do so by preventing tumor ... Specific drugs exploiting these mechanisms include the CTLA-4 targeting agent ipilimumab (Yervoy) and the anti-PDL products nivolumab (Opdivo ...

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented data at the American Association for Cancer Research (AACR) IO Annual Meeting ...

This new agent, like the other DPP-4 inhibitors, has a mechanism of action that affects both pancreatic ß-cell survival as well as ß-cell secretory function. These medications do not incite ...

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today ...